Evidence map›Paper›PMID 40544999›Full record

ReviewTransplantation and cellular therapy2025

The Caregiver Paradigm in Hematopoietic Cell Transplant: Current and Future Directions.

Ben Tweeten, Jill Randall, Anna Barata, Nandita Khera, Melody A Griffith, Anna M DeSalvo, Katie Schoeppner, Jaime M Preussler

Abstract readReview
In one paragraph

Review in Transplantation and cellular therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ben TweetenPatient and Provider Services, NMDP, Minneapolis, Minnesota.
Jill RandallCenter for Improving Patient and Population Health and Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
Anna BarataMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Nandita KheraMayo Clinic Division of Hematology and Medical Oncology, Mayo Clinic Arizona Phoenix, Phoenix, Arizona.
Melody A GriffithMayo Clinic Division of Hematology and Medical Oncology, Mayo Clinic Arizona Phoenix, Phoenix, Arizona.
Anna M DeSalvoCenter for International Blood and Marrow Transplant Research (CIBMTR), NMDP, Minneapolis, Minnesota.
Katie SchoeppnerPatient and Provider Services, NMDP, Minneapolis, Minnesota.
Jaime M PreusslerCenter for International Blood and Marrow Transplant Research (CIBMTR), NMDP, Minneapolis, Minnesota. Electronic address: jpreussl@nmdp.org.

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
NTP INFORMATION SYSTEMS SUPPORT27305C0011 · NIEHS · Z-TECH CORPORATION · 2007 to 2009
$4.3M
Clinical and mechanistic studies defining optimal preparative approaches to infants with IL2RG/JAK3/RAG1/RAG2 SCID: a randomized trial of busulfan dosageU01AI184132 · NIAID · NATIONAL MARROW DONOR PROGRAM · PI JEFFERY J AULETTA, Michael A Pulsipher · 2024 to 2026
$3.2M
Interdisciplinary Research Training Center in Cancer Care DeliveryT32CA236621 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Lauren P Wallner · 2020 to 2026
$2.8M
BMT Core - Pediatric Transplantation and Cellular Therapy Consortium (PTCTC): Providing Clinical Trial Access For Children With Life Threatening DiseasesUG1HL174426 · NHLBI · NATIONAL MARROW DONOR PROGRAM · PI Leslie S Kean, Heather E Stefanski · 2024 to 2026
$513k
PROVIDE RABBITS, RATS, MICE, HAMSTERS, GERBILS, GUINEA PIGS27307C0011 · NIEHS · PI BOLEN, WAYNE · 2007 to 2007
$500k
NCI NIH HHS T32 CA236621NCI NIH HHS U24 CA076518NHLBI NIH HHS UG1 HL174426NIAID NIH HHS U01 AI184132NIEHS NIH HHS 27305C0011NIEHS NIH HHS 27307C0011NIEHS NIH HHS 27398C0011
6 · The paper itself

Abstract

Many transplant centers (TCs) require a patient to have a caregiver 24 hours a day, 7 days a week for a minimum timeframe to proceed with an allogeneic hematopoietic cell transplant (alloHCT). However, this requirement varies across TCs, with timing of requirements varying from no requirements up to 180 days, and there is inconclusive evidence to support the need for this requirement. The current caregiver requirement paradigm can limit access for many patients, besides causing a significant physical, emotional, and financial burden on caregivers. This article reviews literature on the current alloHCT caregiver paradigm and identifies barriers to change. Lastly, it highlights alternative caregiving models that are currently being implemented, as well as opportunities for future directions to improve access, including the need for research on interventions such as remote monitoring, community partnerships, policy changes, and enhanced screening. There is a need for evidence-based patient-centered care models to transform the caregiver paradigm to ensure that all patients can receive the treatment they need, irrespective of whether they have a caregiver. The future of post-alloHCT care demands a shift towards patient-centered, flexible caregiving models that accommodate the diverse needs and circumstances of patients. Such evidence-based changes in the paradigm can help improve access to, and outcomes for, alloHCT.

Indexed as

CaregiversHematopoietic Stem Cell TransplantationHumansAccess barriersCaregiverHematopoietic cell transplantation

Identifiers

PMID40544999
PMCPMC12395758

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.